Exclusive Summary

• Originator patents have expired, offering a high-certainty window to enter the global market supported by worldwide biosimilar and biogeneric penetration policies.
• Driven by over 19 million annual new cancer cases globally, the demand for treating chemotherapy-induced febrile neutropenia presents a massive and rigid clinical need.
• The availability of 100mcg, 150mcg, and 300mcg vial dosage forms enables customized, weight-based precise dosing, establishing a robust differentiated advantage for potential distribution partners.
• Supported by mature biopharmaceutical manufacturing in China, it offers a highly competitive cost-effectiveness ratio and comprehensive compliance dossiers, securing high-profit margins for global distributors.